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From 1 January 2001 to 31 December 2003, we have treated 118 DDH with two harnesses in a double randomised study. The devices was: Coxa-flex (Fig1) (Thamert GmbH, Burgwedel, Germany) and Teuffel Mignon (Fig 2) (Teuffel GmbH, Stuttgard, Germany). The Coxa-flex harness (CF) allows  placing hips in flexion of 90°-100° and abduction of about 50°. This position aims to obtain that femoral head is well-centred and well-aimed in the bottom of the acetabulum, in order to achieve its correct remodelling with time. The flexion also promotes the well-centred and well-aimed action of ileopsoas muscles; this harness is like the Pavlik one [14].
The Teuffel Mignon harness (TM) allows placing hips in controlled abduction of about 60°, with a flexion of about 80°; this position aims to obtain the well-centred and well-aimed femoral head in the bottom of the acetabulum.
Usually in the clinical practice, our choice of harness was determined by Graf sonographic type of hip and age of infant; as a rule, our protocol of treatment is:
1)	Graf type C at any age is treated with TM harness;
2)	Graf type D before 3 months of life is treated with CF harness and after 3 months with TM harness.
3)	Graf types III A and B at any age were always treated with  CF harness.
The choice between both harnesses was performed on the ground of secure CF restraints and of more rigid device of TM. In the neonates below three months of life and with severe DDH, we prefered a harness of secure restraint; in the other cases we chose a more rigid device for stronger babies and with a low grade of DDH.
The patients were submitted to a double blinded randomised study: 59 hips with TM and 59 hips with CF device (Tab. 1). The choice of device is done before performing the sonographic exam, without knowing its result. During the study an orthopaedic surgeon has clinically examined all babies at the same moment by US exam, with Ortolani and Barlow tests and abduction of the thighs. These tests were positive in only 5 hips (4.2%) and only in babies younger than 2 months of life; three in type IIIA and two in type IIIB of Graf’s classification. Moreover, after the clinical exam we have taken notice of the length of limbs and asymmetry of skin folds of buttock and thighs, the last test was meaningful. We have not included type IV hips of Graf: dislocated hip.
The method used for the statistical analysis was: a linear multiple regression model was adopted to describe the relationship between time for remission (outcome) and available predictive variables (covariates). Covariates included in the model were: type of device used (reference category: CF [Coxa-Flex]), pathological type (reference category: IIC [sonographic type of Graf]), age at the beginning of treatment and gender (reference category: female). This kind of model allows to describe the relationship between several covariates and the outcomes and to predict the remission time in those patients with known features.
RESULTS AND DISCUSSION
All hips of this group of patients recovered (Fig. 3a b, 4a b, 5a b). We define a recovered hip as a type Ia or Ib hip according to classification of Graf at the sonographic appearance. The length of the treatment was from a minimum of 35 days on maximum of 120 days, with median length of 86,11 days. The treatment, on the average, started after 43,03 days of life (minimum 1 days on maximum 99 days). Time of recovery was in relation to age of infant and of start of treatment. We have never changed harness because hip not improved. In all hips treatment was finished with the same harness: TM harness mean recovered hips in 72,76 days (minimum 35 and maximum 120 days) and CF harness in 84,35 days (minimum 35 and maximum 120 days) (Tab. 2).
Statistical analysis shows a significant associations between remission and pathological type (P value <0.001), age at diagnosis (P <0.001) and device (P <0.02). Moreover during the study we have never observed significant association with sex (P=0.63). 
We also have never found any case of avascular necrosis in this group of patients; all babies were also clinically checked after three months after starting walking.
Both harnesses seemed to be well tolerated by infants and well managed by parents.
The treatment with harness is useful and clearing up in a greater number of  the DDH showed by sonography.
STATISTICAL ANALYSIS. The linear multiple regression model shows a statistically significant associations between outcome and pathological type (P value<0.001), age at diagnosis (P<0.001) and device (P<0.02). No significant association was found with sex (P=0.63) (Tab. 3).
The estimated model shows that a patient treated with a TM device needs about 7 days more to recover compared to a patient treated with CF. Although this difference is statically significant, the clinical impact of the device’s  choice can’t  be considered meaningful. 
It was found that age at diagnosis is an important predictor from both statistical and clinical point of view. The model shows that a patient would take half a day to recover, for each delayed day in diagnosis. This would imply - for instance - that a patient that is diagnosed a month earlier than another with the same characteristics would need 15 days less to recover. 
Also pathological type is shown statistically and clinically significant in the prediction of time to remission. The model confirms that patients with more serious pathologies needs more time to recover. For instance - on average - the remission of an IIIA patient will take about a month longer than for a patient of type IIC. A pair of wise comparisons showed that pathological types IIC and IID had a different effect on remission time (P<0.05), while IIIA and IIIB did not (P=0.40). There is a significantly different effect between pathological types II and III (all pair wise comparisons with P<0.001).
Example: Estimated time to remission at median age for male patient treated with TM (Tab. 4). 
The model is able to explain about the 60% of the variation in the data. This would suggest that other important covariates might exist and should be included in the model.  (Possibly parental attitude to treatment).
In this study we have compared the efficacy of treatment with CF versus TM harness in a randomised population of developmental dysplasia of the hip. 
During this study we haven’t observed any different of improvement between the two devices. The mean time of recovery of all hips are statistical the same in the two groups of the study (P value <0.001) considering the different degrees of pathology for both harnesses. 
The estimated model shows that - on average-  recovery takes 7 days more with a TM device that with CF. While this difference results statistically significant, the clinical impact of device’s choice can’t be considered important (P<0.02). 
Another important comparison showed by statistical analysis is the meaningful association between age and diagnosis (P<0.02), as a predictor of recovery.
A very significant acquisition showed from statistical analysis is the possibility to estimate the time of recovery on sonographic type of hip (P<0.001). The length of recovery is shorter when  the hip considered is staged as an initial grade of Graf’s classification. These data haven’t relation with age of diagnosis [16, 17].
We can also assert that the safety of both devices is excellent, in this group of patients we have never observed avascular necrosis of the head. This good result depends on the choice of the right device, the accuracy, the frequent clinical and sonographic check-ups of hips and on the parent’s compliance, on co-operation with paediatrics, and finally on probably casual lack of genetic dysplasia in this group of patients.
We can also affirm that both CF and TM harness have maintained the femoral head in the centre of a dysplasic acetabulum (always controlled by US at the moment of positioning harness), allowing our correct remodelling. 
CONCLUSION
We think that the importance in the treatment of DDH isn’t only the type employed device, but it is the correct sonographic diagnosis with Graf’s method, and this is only possible with long experience in sonography of the hip in infants. 
Sonography certainly has some limitations: for instance its results depends on the ability of the operator. A sonographic experienced phisician is really indispensable for a correct exam of the hips, and for a correct interpretation of pictures. We think that a better Sonography executor for infant hip is the orthopaedic paediatrics. If the orthopaedic paediatrics is especially experienced in sonography of the hip, he performs both the sonographic - clinical diagnosis and therapy of the pathological hips: without wasting time.
Moreover it is very important to begin treatment as soon as possible, when the bone of infant hip is more morphologically mouldable and modelling, even though the estimated time of recovery isn’t related with the age of diagnosis [16, 17].
We think that it would be useful that all infants within three months of life undergo sonographic evaluation. 
Ethically we consider correct to treat all DDH showed by sonography.
Last but not least it is the accuracy and frequent clinical and sonographic check-up of hips, good compliance of parents and co-operation with paediatrics; these reduce in a significant way, the incidence of very important complications such as avascular necrosis of the head of the femur.
The treatment with harness is useful and resolutive in all the DDH showed by sonography. We think isn’t fundamental the type of device employed but what is important is the choice of the right one for every case.
Anyway the right choice of the devices is based on experience of the orthopaedic surgeon with that specific one.
Lastly sonography permits follow-ups of hips during treatment.


Tab. I. DDH treated with 2 different devices.





















Time of recovery of the DDH on the base of the Graf’s type and the device employed.
















Statistical analysis: linear multiple regression model for describe the relationship between time to remission (outcome) and available predictive variables (covariates: type of device, age, sex).
Significance codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1 
Residual standard error: 15.65 on 111 degrees of freedom
Multiple R-Squared: 0.59, Adjusted R-squared: 0.57 
F-statistic: 27.45 on 6 and 111 DF, p-value: < 2.2e-16 
° Teuffel Mignon device.
	Estimate	Std. Error	T value	Pr (>|t|)    
(Intercept)	48.16	3.87	12.44		< 2e-16 ***
Device (TM°)	7.37	3.07	2.40	0.0180 *  
Age  	0.55	    		0.06	8.76	2.41 e-14***
type Graf (IID)	8.35 	 	3.27	2.55	0.0121*
Type Graf(IIIA)	31.39    	   			4.69		6.68 		9.67e-10 ***
Type Graf(IIIB)	37.09    	5.80	6.38	4.11e-09***
Sex (M)	1.44	 		2.99	  	0.48	0.6300    
	 
Table IV. 
Estimated time to remission at median age for male patient treated with TM.

DDH Graf  type	Median age	Estimated remission time (days)
IIC	42	80
IID	39	87
IIIA	33	107
IIIB	49	121
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